Last reviewed · How we verify

STZ-5FU

Grupo Espanol de Tumores Neuroendocrinos · Phase 3 active Small molecule

STZ-5FU is a chemotherapeutic agent that works by interfering with DNA synthesis.

STZ-5FU is a chemotherapeutic agent that works by interfering with DNA synthesis. Used for Colorectal cancer, Breast cancer.

At a glance

Generic nameSTZ-5FU
Also known asSTZ based Chemotherapy
SponsorGrupo Espanol de Tumores Neuroendocrinos
Drug classpyrimidine analog
Targetthymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

STZ-5FU is a prodrug that is converted into 5-fluorouracil, which is then incorporated into DNA, causing DNA damage and inhibiting cancer cell growth. This leads to cell death and ultimately, tumor shrinkage.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results